Oramed Pharmaceuticals is a pharmaceutical company focused on the research and development of oral delivery technologies for therapeutic proteins. Its core business involves developing an oral dosage form designed to deliver active insulin and other proteins through the gastrointestinal tract without chemically modifying the active ingredients. The company plans to initiate a US-based clinical trial in 2026 to validate its oral insulin formulation. In addition to its core pharmaceutical activities, the company allocates capital to strategic investments in healthcare and life sciences companies, including significant financial transactions and royalty rights related to Scilex Holding Company products such as ZTLido and SP-103. It also holds exclusive rights to develop and commercialize lidocaine-based products outside the United States through its subsidiary RoyaltyVest Ltd. The company previously entered into a joint venture with Hefei Tianhui Biotech Co., Ltd. to establish OraTech for the development and commercialization of its oral insulin technology, although this agreement was terminated in late 2025.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage oramed.com
Sector Healthcare IR page oramed.com/investors
Tags
oral insulin, protein delivery, pharmaceutical development, healthcare investments, royalty rights, lidocaine products, clinical trials, Oramed Ltd., OraTech, POD, Scilex Holding Company, Scilex Pharmaceuticals Inc., ZTLido, SP-103, RoyaltyVest Ltd., Hefei Tianhui Biotech Co. Ltd., Technowl Limited
Press page oramed.com/category/press-releases

Metrics

Valuation  
Market cap $ 195.033M
Market cap (USD) $ 195.033M
P/E 1.32
PEG —
P/BV 0.58
P/S 97.52
P/OCF -61.82
P/FCF -61.56
Dividend yield —
Turnover / mcap —
Returns  
ROE 37.0%
ROI 41.5%
ROIC -8.3%
Profit margin 3,202.5%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score 26.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Revenue 2M — 1.34M 2.703M 2.703M 2.71M 2.703M 2.449M 2.456M 641K — — — — — —
Net profit 64.05M -19.103M 5.525M -37.764M -22.989M -11.511M -14.355M -12.727M -10.48M -10.964M 7.232M -5.696M -4.232M -3.344M -1.561M —
Free cash flow -9.154M -8.43M -10.549M -28.414M -21.556M -12.522M -12.955M -14.662M -5.838M 4.646M -4.947M -4.082M -3.402M -2.304M -1.708M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009
Share price 2.85 2.42 2.31 12.03 20.11 3.52 3.86 4.9 8.5 8.34 5.8 9.41 7.4 — — —
Price performance 12m 0.18 0.05 -0.81 -0.16 4.71 -0.09 -0.21 -0.42 0.02 0.44 -0.38 0.27 — — — —

Filed figures

Figure Aug 2018 Aug 2019 Aug 2020 Dec 2020 Aug 2021 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) 2.45M 2.7M — — — — — 51M — —
Lease liabilities (USD) — 113,000 75,000 — 533,000 500,000 894,000 609,000 372,000 825,000
Cash and deposits (USD) 5M 3.33M 19.3M 21.6M 77.2M 27.5M 40.5M 9.06M 54.4M 45.9M
Right-of-use assets (USD) — 116,000 75,000 — 533,000 500,000 987,000 694,000 414,000 750,000
Net debt (borrowings + leases - cash) (USD) -2.55M -626,000 — — — — — 42.6M — —
Cash flow detail
Operating cash flow (USD) -14.7M -12.9M -12.4M — -21.2M — -27.9M -10.3M -8.41M -9.15M
Purchases of property, plant and equipment (USD) -5,000 -15,000 -82,000 — -375,000 — -496,000 -254,000 -18,000 -9,000
Change in payables (cash effect) (USD) — — — — — — — -2.23M 3.53M 1.13M
Share buybacks (cash effect) (USD) — — — — — — — — -2.48M -4.74M
Interest paid (cash effect) (USD) — — — — — — — -574,000 -2.32M —
Income taxes paid (cash effect) (USD) — -300,000 — — -563,000 — -1.84M — -2.32M -3.32M
Share-based compensation (USD) 1.55M 808,000 1.17M — 2.7M — 11.5M 4.21M 4.05M 5.99M
Free cash flow (OCF - PPE - intangibles) (USD) -14.7M -13M -12.5M — -21.6M — -28.4M -10.5M -8.43M -9.15M
Income detail
Research and development expense (USD) 12M 13.5M 10.2M — 21M — 27.6M 8.97M 6.32M 6.38M
↳ 5y CAGR +39.4% +32.8% +22.2%
Total comprehensive income (USD) -12.4M -14.4M -11.5M — 22.2M — — — — —
Comprehensive income to owners (USD) -12.4M -14.4M -11.5M — 22.2M — — — — —
Reported Nov 27, 2019 Jan 9, 2020 Nov 24, 2020 May 12, 2022 Mar 6, 2023 May 12, 2022 Mar 6, 2023 Mar 27, 2025 Mar 26, 2026 Mar 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below.

Proposal No. 1 - Re-election of Directors.

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

Director Name For Against Abstain Broker Non-Votes Dr. Daniel Aghion 12,662,432 4,769,203 20,234 7,538,073

Dr. Miriam Kidron 13,672,468 3,756,991 22,410 7,538,073

Nadav Kidron 13,702,335 3,729,485 20,049 7,538,073

Dr. Arie Mayer 11,784,397 5,648,636 18,836 7,538,073

Yehuda Reznick 13,687,270 3,735,295 29,304 7,538,073

Benjamin Shapiro 11,567,510 5,859,953 24,406 7,538,073

1

Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm for the 2026 Fiscal Year.

On June 28, 2026, the board of directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”) approved the Fifth Amended and Restated Bylaws (the “Amended Bylaws”) of the Company, effective as of June 25, 2026. The Fifth Amended and Restated Bylaws amend and restate those certain Fourth Amended and Restated Bylaws of the Company, to (i) revise the record date procedures for stockholder action by written consent by providing that, if the Board of does not fix a record date within the applicable period, the record date will be fixed in accordance with Section 213(b) of the Delaware General Corporation Law, (ii) eliminate former Article III, Section 11(b), which required a stockholder requesting a record date for action by written consent to provide, among other information, certain information regarding the proposed action, related proposals and solicitation plans, and (iii) revise the effectiveness provision for stockholder consents to provide that consents signed by a sufficient number of stockholders must be delivered to the Company in accordance with applicable law within 60 days of the first date on which a consent is delivered to the Company.

NEW YORK, June 17, 2026 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) (www.oramed.com ), announced today that it is set to join the U.S. small cap Russell 2000® and broad-market Russell 3000® Index at the conclusion of the 2026 Russell indexes semi-annual reconstitution. The 2026 Russell 2000 and Russell 3000 reconstitution becomes final after the close of US markets on Friday, June 26, and becomes effective for trading at the market open on Monday, June 29, according to a preliminary list of additions posted by FTSE Russell on May 22, 2026.

Semi-annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, 2026, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.2 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a diversified operating company that deploys capital across the biomedical and broader investment landscape, leveraging deep industry relationships, regulatory expertise, and operational experience to build and actively support a diversified portfolio of holdings. For more information, please visit https://oramed.com/ .

About FTSE Russell:

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

Prompts

Oramed Pharmaceuticals Inc. (ticker ORMP), listed in United States.

Company History

Date Change Detail
Oct 24, 2006 Renamed Integrated Security Technologies, Inc. → ORAMED PHARMACEUTICALS INC.
Jun 14, 2004 Renamed IGUANA VENTURES LTD → Integrated Security Technologies, Inc.

ETFs Holding Oramed Pharmaceuticals Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 55,623 $ 216.93K Nov 16, 2026
DFAS 0.00% 61,115 $ 246.293K Nov 12, 2026
DXUV 0.00% 10,585 $ 42.658K Nov 12, 2026
DFAC 0.00% 59,885 $ 241.337K Nov 12, 2026
DCOR 0.00% 7,654 $ 30.846K Nov 12, 2026
DFUS 0.00% 3,431 $ 13.827K Nov 12, 2026
AVUS 0.00% 4,152 $ 16.193K Nov 16, 2026